Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
Study Information
Alliance Study ID: NCCTG-983252
NCT Study ID (ClinicalTrials.gov): NCT00003612
Alliance Committee: Breast Cancer
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Edith A. Perez, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information